Related Experiment Video
Updated: Aug 6, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
En bloc versus conventional resection of primary bladder tumor: a systematic review and meta-analysis
Pietro Delgado Rezende1, Adriana Sayuri Hashimoto1, Henrique Lepine1
1Division of Urology, Instituto do Câncer do Estado de São Paulo (ICESP), Universidade de São Paulo (USP), São Paulo, SP, Brazil.
Objective:
To provide an updated view comparing the perioperative, functional characteristics and oncological outcomes in patients submitted to cTURBT and ERBT for the diagnosis and treatment of NMIBC.
Methods:
A search of major databases, including Medline, Embase, Lilacs, Scopus, Web of Science, NIH, Clinical Trials, and EU Clinical Trials Register, was conducted up to January 2025, adhering to PRISMA guidelines. Only Randomized Controlled Trials (RCTs) were included. The primary endpoints assessed were perioperative complications and oncological outcomes.
Results:
This study encompasses 16 studies including 2.654 patients. Surgery duration showed a longer time of operation in the ERBT group (MD = 3.09, 95% CI 0.15‒6.03). Also, less time of catheterisation (MD = -0.54, 95% CI -0.97 ‒ -0.11) and shorter length of stay in the ERBT group (MD = -0.83, 95% CI -1.41 ‒ -0.25). The total number of perioperative complications was lower in the ERBT group, although no statistically significant difference was shown between groups. Lastly, the ERBT group was associated with less chance of triggering the obturator reflex (OR = 5.44, 95% CI 1.61‒18.34). Oncological outcomes showed no significant difference between groups.
Conclusion:
ERBT and cTURBT showed no difference in short-term oncological outcomes. Although ERBT did not reduce overall complication rates, it demonstrated a benefit in reducing the occurrence of the obturator reflex and shorter time of hospitalization. Further randomized controlled trials with long-term follow-up and a broad spectrum of tumor sizes are necessary. More randomized controlled trials are needed, focusing on long-term follow-up and a wider range of tumor sizes.
